FDA requests technical updates for Biogen's high dose nusinersen application
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/15/2026
- Wall St set for higher open on Iran deal optimism, lower oil prices
- Fox to acquire Roku for $22 billion to create streaming and live content giant
- SpaceX extends gains premarket after biggest IPO ever values it at $2.1 trillion
- These 2 space stocks were upgraded at KeyBanc today
- Nvidia plans to raise at least $20 billion in bond sale
- This company's long-term growth remains underappreciated: Wolfe
- This stock is the biggest winner from higher voltages in the Datacenter IT room
- Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
- Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
- Why does Barclays say it’s time to buy this Spanish stock?
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
September 23, 2025 4:30 PM EDTCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Companys supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be... More
